Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Holds Up Edwards-DexCom Continuous Glucose Monitor For Hospital Use

This article was originally published in The Gray Sheet

Executive Summary

Edwards Lifesciences' and DexComs’ first-of-its-kind continuous glucose monitor for hospital use is running into delays at FDA.

You may also be interested in...

New Products In Brief

Product approvals and launches from Cardiva, Medtronic and more.

FDA Wants To See New, Improved Hospital Continuous Glucose Monitors

FDA is encouraging industry to submit study designs for newer, more accurate continuous glucose monitors for hospital use. It gathered experts at a June 25 public meeting to discuss questions around indications for use and trial designs.

With FDA Questions Answered, Edwards Expects Sapien Approval “Any Day”

Edwards Lifesciences expects FDA approval of its Sapien transcatheter aortic heart valve replacement “any day,” CEO Michael Mussallem said Oct. 19.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts